Treatment of chemotherapy-associated anemia with the erythropoiesis-stimulating agents (ESAs), epoetin alfa, epoetin beta, and darbepoetin alfa, has been shown to increase Hb levels, thereby reducing the need for transfusions and improving QoL [18-22]. This evidence concerns the gene GSTM1 and anemia (phenotype).